PharmiWeb Recruiter Blog

Company recognized for the fourth consecutive year in U.S., the second year in Canada and India, and first-time certifications in the United Kingdom and Singapore

Singleron Biotechnologies, a leader in single cell multi-omics analysis, is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications.

Educators and school officials encouraged to drive student awareness of state and regional science fairs for a chance to enter nation’s premier middle school STEM competition

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma

– Genomic Biopharma Inc. to present abstracts on two drug candidate programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting –

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity. Genomic Biopharma Inc. will present two abstracts on two drug programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting, the first of which is a top scoring abstract at the meeting titled:

• GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN’S SYNDROME (“SJS”) AND SYSTEMIC LUPUS ERYTHEMATOSUS (“SLE”)
• HANNOVER MEDICAL...

SAN ANTONIO, Oct. 25, 2022 /PRNewswire/ -- Scorpion Biological Services (Scorpion), a fully integrated contract research (CRO) and contract development & manufacturing organization (CDMO) focused on the development of biologic drugs, hosted the grand opening of its new, state-of-the-art San Antonio facility on Friday, October 21, 2022.

• A newly established portfolio company of Syncona Limited will commence a tender offer to acquire all outstanding shares of AGTC for $0.34 per share, valuing AGTC at approximately $23.5 million (£20.8 million[1]), plus the potential for up to an additional $50.0 million (up to $0.73 per share) in contingent value rights in the event certain milestones are achieved
• Acquisition includes AGTC’s lead candidate, AGTC-501, a potentially best-in-class, adeno-associated virus (AAV) gene therapy for X-linked retinitis pigmentosa (XLRP), currently in late-stage clinical development 
• If the transaction is completed, AGTC will be Syncona’s third company focused on retinal gene therapy, following Nightstar and Gyroscope, and will benefit from Syncona’s significant expertise and strategic insight in the field 
• Syncona and AGTC will host a conference call on October 24, 2022 at 7:30 a.m. ET, 12:30 p.m. BST

Syncona Limited, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation ("AGTC") (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialisation of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs) for approximately $23.5 million ($0.34 per share) in cash, an approximately 42% premium to the AGTC closing share price on 21 October 2022. The transaction also includes the potential for up to an additional $50.0 million (up to $0.73 per share) in contingent value rights to AGTC’s stockholders in the event certain milestones related to transactions involving AGTC’s assets and regulatory and commercial milestones related to AGTC’s products are achieved. The board of directors of AGTC unanimously recommends that the stockholders of AGTC tender their shares in the tender offer once it is commenced.  The closing of the tender offer is subject to the tendering by AGTC’s stockholders of a majority of AGTC’s outstanding shares.

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases